















I. Symposium of Young Researchers on 
Pharmaceutical Technology, 
Biotechnology and Regulatory Science 
Institute of Pharmaceutical Technology and 
Regulatory Affairs 
Faculty of Pharmacy 




I. Symposium of Young Researchers on Pharmaceutical Technology, 
Biotechnology and Regulatory Science 
 
Institute of Pharmaceutical Technology and Regulatory Affairs 
Faculty of Pharmacy 










Edited by Tivadar Bíró, Ildikó Csóka 
I. Symposium of Young Researchers on Pharmaceutical Technology, 
Biotechnology and Regulatory Science 




Development of sodium hyaluronate-based formulations loaded with 
nanosuspension for nasal delivery of loratadine: Simplicity of preparation and 
application 
Areen Alshweiat, IIdikó Csóka, Rita Ambrus 
Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 
Szeged, Hungary. 
Faculty of Pharmacy, Interdisciplinary Excellence Centre, Institute of Pharmaceutical Technology and Regulatory 
Affairs, University of Szeged, Szeged, Hungary. 
 
 
The unique requirement for delivery of poorly-water soluble drugs has driven a great deal of 
research into new formulations and routes of administration. Loratadine (LOR) is a H1 
antihistamine drug. It is commonly prescribed for treatment of various allergic conditions. 
According to BCS, LOR is classified as class II drug. Furthermore, LOR exhibits a pH-dependent 
solubility. Consequently, oral administration of LOR is associated with variable and poor 
bioavailability [1]. Moreover, the oral administration of LOR can produce several side effects, 
including hepatotoxicity, and breathing exertion. Thus, alternative routes of administration 
such as nasal could be advantageous to overcome these effects [2]. 
Simple methods were used to prepare the nasal formations (NF). The nanosuspension was 
prepared by ultrasonication precipitation. The concept of Quality by design (QbD) was 
followed to link the critical process parameters (CPPs) with the required critical quality (CQAs) 
attributes and risk assessment to select the optimized CPPs for the preparation of the 
nanosuspensions that were further formulated into NFs using sodium hyaluronate (Na-HA). 
The nanosuspension displayed a particle size of 311.55 nm. The NFs showed an enhanced 
viscosity and mucoadhesive properties. The diffusion was achieved within 1h. The NFs showed 
a drug and Na-HA dependent diffusion. The formula that contains of 5 mg/ml Na-HA and 2.5 
mg/ml LOR showed the highest flux, and permeability coefficient. 
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